Opposite roles of FOXA1 and NKX2-1 in lung cancer progression

Genes Chromosomes and Cancer

Volumn 51, Issue 6, 2012, Pages 618-629

  Deutsch, Lena ^a   Wrage, Michaela ^a   Koops, Susann ^a   Glatzel, Markus ^a   Uzunoglu, Faik G ^a   Kutup, Asad ^a   Hinsch, Andrea ^a   Sauter, Guido ^a   Izbicki, Jakob R ^a   Pantel, Klaus ^a   Wikman, Harriet ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3ALPHA; TRANSCRIPTION FACTOR NKX2.1; TRANSCRIPTION FACTOR NKX2.2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CANCER SURGERY; CHROMOSOME 14Q; CLINICAL ARTICLE; COPY NUMBER VARIATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; GENE TARGETING; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; MALE; NUCLEOTIDE SEQUENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

AGED; BRAIN NEOPLASMS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FEMALE; GENE AMPLIFICATION; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS;

EID: 84859444521     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.21950     Document Type: Article

References (41)

1. Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. 2009. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol 27: 271-278.
2. Au NH, Cheang M, Huntsman DG, Yorida E, Coldman A, Elliott WM, Bebb G, Flint J, English J, Gilks CB, Grimes HL. 2004. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: A tissue microarray study of 284 cases and 18 markers. J Pathol 204: 101-109.
3. Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, Dunn S, Huntsman DG, Nakshatri H. 2007. FOXA1 expression in breast cancer-Correlation with luminal subtype A and survival. Clin Cancer Res 13: 4415-4421.
4. Barlesi F, Pinot D, Legoffic A, Doddoli C, Chetaille B, Torre JP, Astoul P. 2005. Positive thyroid transcription factor 1 staining strongly correlates with survival of patients with adenocarcinoma of the lung. Br J Cancer 93: 450-452.
5. Baudis M. 2007. Genomic imbalances in 5918 malignant epithelial tumors: An explorative meta-analysis of chromosomal CGH data. BMC Cancer 7: 226.
6. Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, Haller A, Lafitte JJ, Sculier JP. 2006. Thyroid transcription factor 1-A new prognostic factor in lung cancer: A meta-analysis. Ann Oncol 17: 1673-1676.
7. Besnard V, Wert SE, Hull WM, Whitsett JA. 2004. Immunohistochemical localization of Foxa1 and Foxa2 in mouse embryos and adult tissues. Gene Expr Patterns 5: 193-208.
8. Boggaram V. 2009. Thyroid transcription factor-1 (TTF-1/Nkx2.1/TITF1) gene regulation in the lung. Clin Sci (Lond) 116: 27-35.
9. Chhieng DC, Cangiarella JF, Zakowski MF, Goswami S, Cohen JM, Yee HT. 2001. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens. Cancer 93: 330-336.
10. DeFelice M, Silberschmidt D, DiLauro R, Xu Y, Wert SE, Weaver TE, Bachurski CJ, Clark JC, Whitsett JA. 2003. TTF-1 phosphorylation is required for peripheral lung morphogenesis, perinatal survival, and tissue-specific gene expression. J Biol Chem 278: 35574-35583.
11. Friedman JR, Kaestner KH. 2006. The Foxa family of transcription factors in development and metabolism. Cell Mol Life Sci 63: 2317-2328.
12. Harris T, Pan Q, Sironi J, Lutz D, Tian J, Sapkar J, Perez-Soler R, Keller S, Locker J. 2011. Both gene amplification and allelic loss occur at 14q13.3 in lung cancer. Clin Cancer Res 17: 690-699.
13. Hayat MJ, Howlader N, Reichman ME, Edwards BK. 2007. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist 12: 20-37.
14. Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA, Jr., Varella-Garcia M, Gandara DR. 2008. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 26: 3351-3357.
15. Hsu DS, Acharya CR, Balakumaran BS, Riedel RF, Kim MK, Stevenson M, Tuchman S, Mukherjee S, Barry W, Dressman HK, Nevins JR, Powers S, Mu D, Potti A. 2009. Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci USA 106: 5312-5317.
16. Jagirdar J. 2008. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med 132: 384-396.
17. Jain RK, Mehta RJ, Nakshatri H, Idrees MT, Badve SS. 2011. High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology 58: 766-772.
18. Jassem J, Skokowski J, Dziadziuszko R, Jassem E, Szymanowska A, Rzyman W, Roszkiewicz A. 2000. Results of surgical treatment of non-small cell lung cancer: Validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg 119: 1141-1146.
19. Jong K, Marchiori E, Meijer G, Vaart AV, Ylstra B. 2004. Breakpoint identification and smoothing of array comparative genomic hybridization data. Bioinformatics 20: 3636-3637.
20. Kendall J, Liu Q, Bakleh A, Krasnitz A, Nguyen KC, Lakshmi B, Gerald WL, Powers S, Mu D. 2007. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci USA 104: 16663-16668.
21. Kwei KA, Kim YH, Girard L, Kao J, Pacyna-Gengelbach M, Salari K, Lee J, Choi YL, Sato M, Wang P, Hernandez-Boussard T, Gazdar AF, Petersen I, Minna JD, Pollack JR. 2008. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 27: 3635-3640.
22. Lin L, Miller CT, Contreras JI, Prescott MS, Dagenais SL, Wu R, Yee J, Orringer MB, Misek DE, Hanash SM, Glover TW, Beer DG. 2002. The hepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13 is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer Res 62: 5273-5279.
23. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS, Brown M. 2008. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 132: 958-970.
24. Mehta RJ, Jain RK, Leung S, Choo J, Nielsen T, Huntsman D, Nakshatri H, Badve S. 2012. FOXA1 is an independent prognostic marker for ER-positive breast cancer. Breast Cancer Res Treat 31: 881-890.
25. Minoo P, Hu L, Xing Y, Zhu NL, Chen H, Li M, Borok Z, Li C. 2007. Physical and functional interactions between homeodomain NKX2.1 and winged helix/forkhead FOXA1 in lung epithelial cells. Mol Cell Biol 27: 2155-2165.
26. Moasser MM. 2007. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 26: 6577-6592.
27. Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, Pontecorvi A, Nose V, Loda M, Brown M. 2009. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res 15: 3680-3689.
28. Perner S, Wagner PL, Soltermann A, LaFargue C, Tischler V, Weir BA, Weder W, Meyerson M, Giordano TJ, Moch H, Rubin MA. 2009. TTF1 expression in non-small cell lung carcinoma: Association with TTF1 gene amplification and improved survival. J Pathol 217: 65-72.
29. Song Y, Washington MK, Crawford HC. 2010. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Cancer Res 70: 2115-2125.
30. Stenhouse G, Fyfe N, King G, Chapman A, Kerr KM. 2004. Thyroid transcription factor 1 in pulmonary adenocarcinoma. J Clin Pathol 57: 383-387.
31. Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, Tomida S, Shimada Y, Osada H, Kosaka T, Matsubara H, Mitsudomi T, Sekido Y, Tanimoto M, Yatabe Y, Takahashi T. 2007. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 67: 6007-6011.
32. Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, Gazdar AF, Fujimoto J, Moran C, Varella-Garcia M, Lee JJ, Hong WK, Wistuba II. 2011. Abnormalities of the TITF-1 Lineage-specific oncogene in NSCLC: Implications in lung cancer pathogenesis and prognosis. Clin Cancer Res 17: 2434-2443.
33. Thatcher N, Manegold C. 2007. Achieving survival improvement in thoracic tumours: from therapeutic strategy management to pharmacogenomics. Lung Cancer 57( Suppl 2): S1-S2.
34. van den Ijssel P, Tijssen M, Chin SF, Eijk P, Carvalho B, Hopmans E, Holstege H, Bangarusamy DK, Jonkers J, Meijer GA, Caldas C, Ylstra B. 2005. Human and mouse oligonucleotide-based array CGH. Nucleic Acids Res 33: e192.
35. Wan H, Dingle S, Xu Y, Besnard V, Kaestner KH, Ang SL, Wert S, Stahlman MT, Whitsett JA. 2005. Compensatory roles of Foxa1 and Foxa2 during lung morphogenesis. J Biol Chem 280: 13809-13816.
36. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA, Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y, Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A, Lin L, Lindeman N, Mardis ER, McPherson JD, Minna JD, Morgan MB, Nadel M, Orringer MB, Osborne JR, Ozenberger B, Ramos AH, Robinson J, Roth JA, Rusch V, Sasaki H, Shepherd F, Sougnez C, Spitz MR, Tsao MS, Twomey D, Verhaak RG, Weinstock GM, Wheeler DA, Winckler W, Yoshizawa A, Yu S, Zakowski MF, Zhang Q, Beer DG, Wistuba II, Watson MA, Garraway LA, Ladanyi M, Travis WD, Pao W, Rubin MA, Gabriel SB, Gibbs RA, Varmus HE, Wilson RK, Lander ES, Meyerson M. 2007. Characterizing the cancer genome in lung adenocarcinoma. Nature 450: 893-898.
37. Wikman H, Nymark P, Vayrynen A, Jarmalaite S, Kallioniemi A, Salmenkivi K, Vainio-Siukola K, Husgafvel-Pursiainen K, Knuutila S, Wolf M, Anttila S. 2005. CDK4 is a probable target gene in a novel amplicon at 12q13.3-q14.1 in lung cancer. Genes Chromosomes Cancer 42: 193-199.
38. Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM, Hubbard DD, DuPage MJ, Whittaker CA, Hoersch S, Yoon S, Crowley D, Bronson RT, Chiang DY, Meyerson M, Jacks T. 2011. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 473: 101-104.
39. Woelfle U, Cloos J, Sauter G, Riethdorf L, Jänicke F, van Diest P, Brakenhoff R, Pantel K. 2003. Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res 15: 5679-5684.
40. Wrage M, Ruosaari S, Eijk PP, Kaifi JT, Hollmen J, Yekebas EF, Izbicki JR, Brakenhoff RH, Streichert T, Riethdorf S, Glatzel M, Ylstra B, Pantel K, Wikman H. 2009. Genomic profiles associated with early micrometastasis in lung cancer: Relevance of 4q deletion. Clin Cancer Res 15: 1566-1574.
41. Zhou L, Lim L, Costa RH, Whitsett JA. 1996. Thyroid transcription factor-1, hepatocyte nuclear factor-3beta, surfactant protein B, C, and Clara cell secretory protein in developing mouse lung. J Histochem Cytochem 44: 1183-1193.